[1] A. Mor, S.B. Abramson, M.H. Pillinger, The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction, Clin. Immunol. 115 (2) (2005) 118–128.
[2] J. Alam, I. Jantan, S.N.A. Bukhari, Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy, Biomed. Pharmacother. 92 (2017) 615–633.
[3] L. Kearsley-Fleet, R. Davies, D. De Cock, K.D. Watson, M. Lunt, M.H. Buch, J. D. Isaacs, K.L. Hyrich, B.-R.C. Group, Biologic refractory disease in rheumatoid arthritis: results from the British society for rheumatology biologics register for rheumatoid arthritis, Ann. Rheum. Dis. 77 (10) (2018) 1405–1412.
[4] G. Schett, P. Emery, Y. Tanaka, G. Burmester, D.S. Pisetsky, E. Naredo, B. Fautrel, R. van Vollenhoven, Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions, Ann. Rheum. Dis. 75 (8) (2016) 1428–1437.
[5] K.T. Aletaha D, J.S. Smolen, Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis, Ann. Rheum. Dis. 62 (2003) 482–486.
[6] A.V. Hadjinicolaou, M.K. Nisar, S. Bhagat, H. Parfrey, E.R. Chilvers, A.J. Ostor, Non-infectious pulmonary complications of newer biological agents for rheumatic diseases–a systematic literature review, Rheumatology 50 (12) (2011) 2297–2305.
[7] J. Yazdany, R.A. Dudley, R. Chen, G.A. Lin, C.W. Tseng, Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D, Arthritis & rheumatology, (Hoboken, N.J.) 67 (6) (2015) 1474–1480.
[8] R. Garcia-Carbonell, A.S. Divakaruni, A. Lodi, I. Vicente-Suarez, A. Saha, H. Cheroutre, G.R. Boss, S. Tiziani, A.N. Murphy, M. Guma, Critical role of glucose metabolism in rheumatoid arthritis fibroblast-like synoviocytes, Arthritis Rheumatol. (Hoboken, N.J.) 68 (7) (2016) 1614–1626.
[9] J. Falconer, A.N. Murphy, S.P. Young, A.R. Clark, S. Tiziani, M. Guma, C. D. Buckley, Review: synovial cell metabolism and chronic inflammation in rheumatoid arthritis, Arthritis Rheumatol. (Hoboken, N.J.) 70 (7) (2018) 984–999.
[10] P.G. de Oliveira, M. Farinon, E. Sanchez-Lopez, S. Miyamoto, M. Guma, Fibroblast- like synoviocytes glucose metabolism as a therapeutic target in rheumatoid arthritis, Front. Immunol. 10 (2019) 1743.
[11] V.H. Matthew G, Lewis C. Cantley, Craig B. Thompson, Understanding the warburg effect: the metabolic requirements of cell proliferation, Science 324 (5930) (2009) 1029–1033.
[12] L.A. O’Neill, R.J. Kishton, J. Rathmell, A guide to immunometabolism for immunologists, Nat. Rev. Immunol. 16 (9) (2016) 553–565.
[13] R.A. Cairns, I.S. Harris, T.W. Mak, Regulation of cancer cell metabolism, Nat. Rev. Canc. 11 (2) (2011) 85–95.
[14] A. Petrasca, J.J. Phelan, S. Ansboro, D.J. Veale, U. Fearon, J.M. Fletcher, Targeting bioenergetics prevents CD4 T cell–mediated activation of synovial fibroblasts in rheumatoid arthritis, Rheumatology 59 (10) (2020) 2816–2828.
[15] M.C. Haerdi-Landerer, M.M. Suter, A. Steiner, M.M. Wittenbrink, A. Pickl, B. A. Gander, In vitro cell compatibility and antibacterial activity of microencapsulated doxycycline designed for improved localized therapy of septic arthritis, J. Antimicrob. Chemother. 61 (2) (2008) 332–340.
[16] M.C. Haerdi-Landerer, A. Steiner, M.M. Suter, Primary bovine synoviocyte cultures: a useful tool for in vitro drug testing? Vet. J. 188 (1) (2011) 58–63.
[17] M. Hanabayashi, N. Takahashi, Y. Sobue, S. Hirabara, N. Ishiguro, T. Kojima, Hyaluronan oligosaccharides induce MMP-1 and -3 via transcriptional activation of NF-kappaB and p38 MAPK in rheumatoid synovial fibroblasts, PloS One 11 (8) (2016), e0161875.
[18] Y. Kanda, Investigation of the freely available easy-to-use software ’EZR’ for medical statistics, Bone Marrow Transplant. 48 (3) (2013) 452–458.
[19] K. Terabe, Y. Ohashi, S. Tsuchiya, S. Ishizuka, C.B. Knudson, W. Knudson, Chondroprotective effects of 4-methylumbelliferone and hyaluronan synthase-2 overexpression involve changes in chondrocyte energy metabolism, J. Biol. Chem. 294 (47) (2019) 17799–17817.
[20] A. Zabek, J. Swierkot, A. Malak, I. Zawadzka, S. Deja, K. Bogunia-Kubik, P. Mlynarz, Application of (1)H NMR-based serum metabolomic studies for monitoring female patients with rheumatoid arthritis, J. Pharmaceut. Biomed. Anal. 117 (2016) 544–550.
[21] U. Fearon, M. Canavan, M. Biniecka, D.J. Veale, Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis, Nat. Rev. Rheumatol. 12 (7) (2016) 385–397.
[22] X.Y. Yang, K.D. Zheng, K. Lin, G. Zheng, H. Zou, J.M. Wang, Y.Y. Lin, C.M. Chuka, R.S. Ge, W. Zhai, J.G. Wang, Energy metabolism disorder as a contributing factor of rheumatoid arthritis: a comparative proteomic and metabolomic study, PloS One 10 (7) (2015), e0132695.
[23] D.R.D. Arne N Wick, I Nakada Henry, Jack B. Wlofe, Localization of the primary metabolic block produced by 2-Deoxyglucose, J. Biol. Chem. 224 (1956) 963–969.
[24] M.G.W. Chen, The inhibition of bovine heart hexokinase by 2-deoxy-d-glucose-6- phosphate: characterization by 31P NMR and metabolic implications, Biochimie 74 (9–10) (1992) 767–873.
[25] M.E.G. Adam, J. Shaywitz, CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals, Annu. Rev. Biochem. 68 (1999) 821–861.
[26] M.M. Bernhard, Mayr Transcriptional regulation by the phosphorylation dependent-factor CREB, Nat. Rev. Mol. Cell Biol. 2 (2001) 599–609.
[27] M. Grunstein, Histone acetylation in chromatin structure and transcription, Nature 389 (1997) 349–352.
[28] N.S. Yuko Takeba, Sueshige Wakisaka, Mitsuhiro Takeno, Atsushi Kaneko, Tomiaki Asai, Tsuyoshi Sakane, Involvement of cAMP responsive element binding protein (CREB) in the synovial cell hyperfunction in patients with rheumatoid arthritis, Clin. Exp. Rheumatol. 18 (2000) 47–55.
[29] T. Nakajima, S. Aratani, M. Nakazawa, T. Hirose, H. Fujita, K. Nishioka, Implications of transcriptional coactivator CREB binding protein complexes in rheumatoid arthritis, Mod. Rheumatol. 14 (1) (2004) 6–11.
[30] J. Song, M.J. Duncan, G. Li, C. Chan, R. Grady, A. Stapleton, S.N. Abraham, A novel TLR4-mediated signaling pathway leading to IL-6 responses in human bladder epithelial cells, PLoS Pathog. 3 (4) (2007), e60.
[31] A. Ishizu, A. Abe, Y. Miyatake, T. Baba, C. Iinuma, U. Tomaru, T. Yoshiki, Cyclic AMP response element-binding protein is implicated in IL-6 production from arthritic synovial cells, Mod. Rheumatol. 20 (2) (2010) 134–138.
[32] A. Riemann, A. Ihling, B. Schneider, M. Gekle, O. Thews, Impact of Extracellular Acidosis on Intracellular pH Control and Cell Signaling in Tumor Cells, Springer New York, New York, NY, 2013, pp. 221–228.
[33] P. Geborek, T. Saxne, H. Pettersson, F.A. Wollheim, Synovial fluid acidosis correlates with radiological joint destruction in rheumatoid arthritis knee joints, J. Rheumatol. 16 (4) (1989) 468–472.